摘要
目的探究艾司西酞普兰联合阿立哌唑治疗精神分裂伴抑郁症的临床疗效及对患者血清神经营养因子-3(NT-3)、去甲肾上腺素(NE)和钙结合蛋白(S100-β)等指标的影响。方法选取2018年1月到2020年6月医院收治的92例精神分裂症伴随抑郁症患者,随机分为观察组和对照组,每组46例。对照组予阿立哌唑治疗,观察组予艾司西酞普兰联合阿立哌唑治疗,持续16周。评估患者治疗前和治疗16周后简明精神病评定量表(BPRS)分数、帕金森症生活质量问卷(PDQ-39)分数、汉密尔顿抑郁量表(HAMD)分数和汉密尔顿焦虑量(HAMA)分数。分别于治疗前和治疗16周后,检测患者血清中多巴胺(DA)、5-羟色胺(5-HT)、NE、S100-β、白介素-6(IL-6)和NT-3水平。记录治疗期间的药物不良反应。结果治疗16周后,2组患者BPRS、PDQ-39、HAMD和HAMA评分均较治疗前降低,且观察组低于对照组(P<0.05);2组患者DA、5-HT和NE水平均高于治疗前,且观察组高于对照组(P<0.05);2组IL-6和S100-β水平较治疗前降低,且观察组低于对照组;NT-3水平较治疗前升高,且观察组高于对照组(P<0.05)。对照组不良反应发生率和观察组之间差异无统计学意义(17.39%vs 21.74%,P>0.05)。结论艾司西酞普兰联合阿立哌唑治疗可以改善精神分裂伴抑郁症患者焦虑抑郁情绪及神经功能,提高患者生活质量。
AIM To explore the effects of escitalopram combined with aripiprazole on levels of serum neurotrophin-3(NT-3),norepinephrine(NE)and calcium-binding protein(S100-β)in patients with schizophrenia with depression.METHODS A total of 92 patients with schizophrenia and depression admitted to the hospital were enrolled between January 2018 and June 2020.They were randomly divided into observation group and control group,with 46 patients in each group.The control group was treated with aripiprazole,while the observation group was treated with escitalopram and aripiprazole for 16 weeks.Before treatment and after 16 weeks of treatment,scores of brief psychiatric rating scale(BPRS),Parkinson’s disease quality of life questionnaire(PDQ-39),Hamilton depression scale(HAMD)and Hamilton anxiety amount(HAMA),levels of dopamine(DA),5-hydroxytryptamine(5-HT),NE,S100-β,interleukin-6(IL-6)and NT-3 were assessed.The adverse drug reactions during treatment were recorded.RESULTS After 16 weeks of treatment,BPRS,PDQ-39,HAMD and HAMA scores were lower than those before treatment in 2 groups,which were lower in observation group than control group(P<0.05).After 16 weeks of treatment,levels of DA,5-HT and NE were higher than those before treatment in 2 groups,which were higher in observation group than control group(P<0.05).After 16 weeks of treatment,levels of IL-6 and S100-βwere lower than those before treatment in 2 groups,which were lower in observation group than control group(P<0.05),while NT-3 level was higher than that before treatment,which was higher in observation group than control group(P<0.05).There was no significant difference in incidence of adverse drug reactions between control group and observation group(17.39%vs 21.74%)(P>0.05).CONCLUSION Escitalopram combined with aripiprazole treatment can effectively improve the anxiety,depression,and neurological function of patients with schizophrenia and depression,and improve the quality of life of patients.
作者
周海腾
邵学克
潘哲拓
ZHOU Haiteng;SHAO Xueke;PAN Zhetuo(Department of Psychiatry,Corning Hospital Affiliated to Wenzhou Medical University,Wenzhou 325000,China)
出处
《中国临床药学杂志》
CAS
2022年第3期210-214,共5页
Chinese Journal of Clinical Pharmacy
